Tasquinimod (S100A9/HDAC4 inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-02-27 — Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF): Phase 1/2 open-label trial (trial-early) evaluating tasquinimod as monotherapy and in combination with ruxolitinib in PMF, post-PV MF, and post-ET MF — first-in-class S100A9/HDAC4 inhibitor mechanism being introduced into the myelofibrosis therapeutic landscape. (novelty: 4)
Open questions
Related
Contributing findings
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
27-feb-2026
novelty 4
per-area 5
introduces